ACQUISITION OF A SOLiD 3 SEQUENCER

描述（由申请人提供）： 斯隆凯特琳研究所要求SOLiD 3测序仪。科学家将使用这台仪器以令人难以置信的深度和极高的精度对整个或部分基因组进行测序。该仪器将使各种生物应用，如从头测序，表观基因组学，突变检测，转录组分析和宏基因组学。所要求的仪器将使斯隆-凯特琳研究所的测序能力增加一倍，从而将周转时间减少到3至4周（目前为8周）。SOLiD 3方法基于与染料标记的寡核苷酸的顺序连接。该技术以其令人难以置信的高精度、超高通量能力和应用灵活性推进了生物研究，特别是癌症研究。每个核苷酸在测序期间被询问两次。该技术减少了测量误差，并产生了适用于检测序列变异（包括罕见变异）的高度准确的序列数据。NIH支持的主要用户包括（1）Scott Keeney博士，他正在研究Spo 11在启动重组的DNA双链断裂中的作用; Eric Lai博士，他正在使用果蝇作为模型系统，以更好地了解Notch信号和microRNA对发育模式的影响; Samuel Singer博士，他正在采取综合方法从分子和生物化学方面表征脂肪肉瘤亚型。该仪器还将支持斯隆凯特琳研究所所有项目的研究人员的一些更温和的项目：癌症生物学和遗传学（琼·马萨格），分子生物学（约翰·佩特里尼），免疫学（迈克尔·格利克曼），人类肿瘤学和发病机制（查尔斯·索耶，大卫索利特，罗斯·莱文）和发育生物学（凯瑟琳安德森，玛丽贝利斯）。SOLiD 3测序仪将位于MSKCC的基因组学核心实验室。这个微阵列和DNA测序核心设施自8年前成立以来一直由Agnes Viale博士领导。公共卫生相关性声明：所要求的仪器将由纪念斯隆-凯特琳癌症中心的科学家用于基因组测序。此次收购将大大提高这些MSKCC研究工作的步伐。

DESCRIPTION (provided by applicant): The Sloan Kettering Institute requests a SOLiD 3 sequencer. This instrument will be used by scientists to sequence whole or parts of genomes at incredible depth and with extreme accuracy. This instrument will enable various biological applications such as de novo sequencing, epigenomics, mutation detection, transcriptome profiling and metagenomics. The requested instrument will double the sequencing capability of the Sloan Kettering Institute and thereby reduce the turnaround time to 3 to 4 weeks (from 8 weeks currently). The SOLiD 3 methodology is based on sequential ligation with dye-labeled oligonucleotides. This technology advances biological research, particularly cancer research, with its incredibly high accuracy, ultra-high throughput capability and application flexibility. Each nucleotide is interrogated twice during sequencing. This technique reduces measurement errors and produces highly accurate sequence data suitable for the detection of sequence variation, including rare variants. NIH-supported major users include (1) Dr. Scott Keeney, who is studying the role of Spo11 in DNA double-strand breaks that initiate recombination; Dr. Eric Lai, who is using Drosophila as a model system to better understand the effect of Notch signaling and microRNAs on developmental patterning; and Dr. Samuel Singer, who is taking an integrative approach to characterize liposarcoma subtypes molecularly and biochemically. This instrument will also be supporting some more modest projects from investigators affiliated with all the programs in the Sloan Kettering institute: Cancer Biology and Genetics (Joan Massague), Molecular Biology (John Petrini), Immunology (Michael Glickman), Human Oncology and Pathogenesis (Charles Sawyers, David Solit, Ross Levine), and Developmental Biology (Kathryn Anderson, Mary Baylies). The SOLiD 3 sequencer will be located in the Genomics Core Laboratory of MSKCC. This microarray and DNA sequencing core facility has been directed by Dr. Agnes Viale since its inception 8 years ago. Public Health Relevance Statement: The requested instrument will be used by scientists at Memorial Sloan-Kettering Cancer Center to sequence genomes. This acquisition will greatly enhance the pace of these MSKCC research efforts.